Ivermectin + albendazole

Full Generic Medicine Info
Dosage/Direction for Use

Nematode infestations
Adult: Per tab contains ivermectin 3 or 6 mg and albendazole 400 mg: 1 tab once daily.
Hypersensitivity. Pregnancy, lactation. child <5 yrs or <15 kg body weight.
Adverse Reactions
Diarrhoea, nausea, vomiting, dizziness, pruritus, urticaria, rash, arthralgia, fever, myalgia, asthenia, postural hypotension, tachycardia, oedema, lymphadenopathy, sore throat, cough, headache, somnolence, transient eosinophilia, raised liver enzyme values.
Drug Interactions
Cimetidine increases albendazole metabolism. Serum levels are increased if taken with dexamethasone and praziquantel agent.
Ivermectin selectively binds and with high affinity to glutamate-gated and GABA (GABA)-gated chloride ion channels. This increases the permeability of the cell membrane to chloride ions leading to hyperpolarisation of muscles and nerve cells, thus ultimately causing paralysis and death of the parasites. Albendazole causes degenerative alterations in the intestinal cells of the worm by inhibiting polymerisation or assembly of tubules into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer and subsequent release of lysosomes result in decreased production of ATP (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilised and eventually dies.
CIMS Class
ATC Classification
D11AX22 - ivermectin ; Belongs to the class of other dermatologicals.
P02CA03 - albendazole ; Belongs to the class of benzimidazole derivative agents. Used as antinematodal.
P02CF01 - ivermectin ; Belongs to the class of avermectine agents. Used as antinematodal.
Disclaimer: This information is independently developed by CIMS based on ivermectin + albendazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in